Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4399450 | 0.86 | CASR (0.44) | TP53KMT2A | |
| SCHEMBL4400761 | 0.85 | KMT2A (0.44) | HTTALDH1A1CHRM3KMT2APOLB | |
| SCHEMBL4391981 | 0.84 | MAPT (0.45) | HTTTP53ALDH1A1CHRM3KMT2A | |
| SCHEMBL4393787 | 0.84 | CASR (0.42) | KMT2A | |
| SCHEMBL13672947 | 0.83 | ALDH1A1 (0.34) | TP53ALDH1A1NPC1RAB9ACHRM3 | |
| SCHEMBL14472756 | 0.83 | MLNR (0.35) | TP53ALDH1A1NPC1RAB9ACHRM3 | |
| SCHEMBL4391651 | 0.81 | EPHX2 (0.38) | TP53ALDH1A1CHRM3KMT2A | |
| SCHEMBL4391985 | 0.81 | CXCR4 (0.37) | SIGMAR1ALDH1A1CHRM3 | |
| SCHEMBL4396219 | 0.81 | CHRM3 (0.49) | CHRM3 | |
| SCHEMBL4391341 | 0.81 | EPHX2 (0.37) | TP53ALDH1A1CHRM3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605261-B2 | Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | AMGEN INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20070173502-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | AVENTIS PHARMA S.A. (FR) | 2007-07-26 | — | — | US | disclosed |
| US-20040053925-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | PROSKELIA SAS (FR) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053925-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | HRH4, HRH2, RPS2 | HTT 2354/4885SIGMAR1 12/4885GAA 3815/4885 |
| US-20070173502-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | RPS2, NOX5, PRMT5 | HTT 2202/4885SIGMAR1 18/4885GAA 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.